Table 2.

Overview of results from studies using subcutaneous immunoglobulin (SCIG) and intravenous immunoglobulin (IVIG) for replacement therapy and immunomodulation in multi-focal motor neuropathy (MMN)

Number of patients	Study design SCIG switch	Primary end-point	Result	Number continuing with SCIG*	Study
10	50% dose (n = 5)	Muscle strength	50% SCIG < IVIG	0/4	Eftimov et al., 2009 [29]
	100% dose (n = 5)		100% SCIG = IVIG	4/5
9	100% dose	Muscle strength	SCIG = IVIG	5/9	Harbo et al., 2009 [28]
	SCIG–IVIG cross-over
8	100% dose	Muscle strength	SCIG = IVIG	7/7	Misbah et al., [30]

^*Patients who completed the study and for whom data were analysed.